AMERICAN SOCIETY OF HEMATOLOGY

BUD · Budget/Appropriations

Public health program funding Federal research funding Advanced Research Projects Agency for Health (ARPA-H) Impact of restructuring and reorganization of federal public health and research agencies FY 2027 NIH funding FY 2027 AHRQ funding FY 2027 CDC funding FY 2027 funding for CDC Sickle Cell Data Collection program FY 2027 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program FY 2027 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP) FY 2027 Department of Veterans Affairs research funding FY 2027 funding for Pediatric Specialty Loan Repayment Program

MED · Medical/Disease Research/Clinical Labs

Sickle cell disease/trait issues Hematology/oncology treatment issues Hematology/oncology drug research and approval issues General hematology public health and research issues Issues impacting laboratory testing and pediatric reference intervals (PRIs) Clinical trials regulations and coverage Issues impacting drug shortages FDA guidance impacting hematology Impact of restructuring and reorganization of federal public health and research agencies Issues related to vaccines and immunization practices for individuals with hematologic disorders

MMM · Medicare/Medicaid

Coverage of blood transfusions under Medicare hospice benefit Medicare physician reimbursement issues CMS national coverage determinations Medicaid coverage for sickle cell disease Issues related to telehealth and extension of telehealth flexibilities Sickle cell disease/trait issues, including coverage for cell and gene therapies Prior authorization Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169) Dental coverage for Medicare beneficiaries Sickle cell disease quality measures Issues impacting drug shortages Access to safe and effective vaccines Issues related to CAR-T/cellular and gene therapies Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma Local Coverage Decisions for next generation sequencing Medicare Patient Access and Practice Stabilization Act of 2025 (H.R. 879) Issues related to Social Security Administration disability evaluations for sickle cell disease Impact of Medicaid funding cuts on hematology Medicare codes for Chronic Care Management (CCM) and Principal Care Management (PCM) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)

Literal federal measure citations: H.R. 879, S. 721, H.R. 5178, S. 1936, H.R. 3514, S. 1816, H.R. 4206, S. 1261

HCR · Health Issues

Hematology/oncology drug research and approval issues Clinical trials regulations and coverage Issues impacting coverage for hematologic diseases and conditions Implementation of No Surprises Act (P.L. 116-260) Sickle cell disease/trait issues Issues related to maternal health care and hematology Issues related to healthcare workforce Issues impacting drug shortages Sickle cell disease quality measures FDA guidance impacting hematology Access to safe and effective vaccines Impact of restructuring and reorganization of federal public health and research agencies Issues related to H-1B visas for physician workforce Sickle Cell Disease Comprehensive Care Act (S. 721 / H.R. 5178) Implementation of One Big Beautiful Bill Act (Public Law No. 119-21) Improving Access to Transfusion Care for Hospice Patients Act (S. 1936) Improving Seniors Timely Access to Care Act (H.R. 3514 / S. 1816) CONNECT for Health Act (H.R. 4206 / S. 1261)

Literal federal measure citations: S. 721, H.R. 5178, S. 1936, H.R. 3514, S. 1816, H.R. 4206, S. 1261